small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 87 results

Industry

Government Contracts & Grants

Winston & Strawn’s Government Contracts & Grants Practice is a nationally recognized, highly regarded group of lawyers with deep experience in handling high-value, and often contentious, government contract disputes, bid protests, and claims across a broad spectrum of industries and issues. Our team also counsels clients on significant regulatory, compliance, and transactional matters—predominantly private equity and M&A deals....Read more

Practice Area

Government Program Fraud, False Claims Act & Qui Tam Litigation

Investigations and litigation involving alleged fraud against the government pose a significant and growing threat to organizations and individuals across all industries that engage directly or indirectly in business with federal, state, and/or local governments. The government makes aggressive use of its extensive criminal and civil investigatory powers to root out alleged fraud and abuse implicating government funds, including one of its most powerful civil enforcement tools—the federal False Claims Act (FCA)—and similar state false claims statutes....Read more

Practice Area

Environmental, Social & Governance (ESG)

Winston’s Environmental, Social, & Governance (ESG) Advisory Team synthesizes the firm’s multidisciplinary experience to help boards, management teams, and investors oversee the complete spectrum of ESG-related legal and business issues. ...Read more

Insights & News 4,155 results

Capital Markets & Securities Law Watch

|

May 7, 2025

|

2 Min Read

Tariff Disclosure Considerations for Form 10-Q

Since January 2025, President Donald J. Trump has issued a series of executive orders imposing new tariffs on global imports. As public companies prepare their first quarter 10-Qs, it’s crucial to reassess and update disclosures related to these tariff changes. Generally, public companies that are or are reasonably likely in the future to be affected by tariffs must disclose the implications of the current tariff regime and likely future tariff changes....Read more

Capital Markets & Securities Law Watch

|

May 6, 2025

|

6 Min Read

New SEC Guidance: Clawback Checkbox Compliance and De-SPAC Disclosures

On April 11, 2025, the SEC’s Division of Corporation Finance issued six new Compliance and Disclosure Interpretations (C&DIs) regarding (i) clawback-related checkboxes on the cover page of Form 10-K and (ii) disclosure required by Regulation S-K Item 402(w)(2). These C&DIs provide crucial guidance for listed issuers on reporting corrections of errors in financial statements and analyzing the implications for executive compensation recovery.

The SEC staff also added a C&DI addressing whether target companies in de-SPAC transactions may suspend their Section 15(d) reporting obligations after closing.

Article

|

May 5, 2025

|

9 Min Read

A Look At AI Benefits And Risks In Global Development Efforts

This article was originally published in Law360. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only....Read more
View All Insights & News

Other Results 132 results

Site Content

What Is Environmental, Social, and Governance (ESG)?

Environmental, Social, and Governance (ESG) refers to non-financial factors that investors and stakeholders may consider to assess company operations and performance. These criteria have come to prominence as investors, particularly “socially responsible investors,” have used ESG to screen potential investments and as a measure of risks and opportunities that could impact a company’s ability to create long-term value....Read more

Site Content

Government Contracts & National Security Policies

Law Glossary

What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?

Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising